Search research articles
Contact Us
Filters
Showing results (11-20 of 35) with videos related to
Page
of 4
Sort By:
Cancers
|
May 14, 2022
An Explorative Study of the Incidental High Renal Excretion of [<sup>18</sup>F]PSMA-1007 for Prostate Cancer PET/CT Imaging
Youssra Allach, Amina Banda, Willemijn van Gemert, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 14, 2022
Thoughts on "Tumor Sink Effect in <sup>68</sup>Ga-PSMA-11 PET: Myth or Reality?"
Bastiaan M Privé, Steffie M B Peters, Maike J M Uijen, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
August 5, 2022
[<sup>89</sup>Zr]Zr-PSMA-617 PET/CT in biochemical recurrence of prostate cancer: first clinical experience from a pilot study including biodistribution and dose estimates
Florian Rosar, Andrea Schaefer-Schuler, Mark Bartholomä, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
February 10, 2023
Population pharmacokinetic dosimetry model using imaging data to assess variability in pharmacokinetics of <sup>177</sup> Lu-PSMA-617 in prostate cancer patients
Hinke Siebinga, Bastiaan M Privé, Steffie M B Peters, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
July 4, 2021
Intra-therapeutic dosimetry of [<sup>177</sup>Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome
Steffie M B Peters, Bastiaan M Privé, Maarten de Bakker, et al.
Nuclear Medicine Communications
|
January 4, 2023
Kidney absorbed radiation doses for [ 177 Lu]Lu-PSMA-617 and [ 177 Lu]Lu-PSMA-I&T determined by 3D clinical dosimetry
Maike J M Uijen, Bastiaan M Privé, Carla M L van Herpen, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
February 22, 2023
Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies
Bastiaan M Privé, Mohamed A Boussihmad, Bart Timmermans, et al.
EJNMMI Research
|
January 24, 2023
Optimization of the radiation dosimetry protocol in Lutetium-177-PSMA therapy: toward clinical implementation
Steffie M B Peters, Maaike C T Mink, Bastiaan M Privé, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
December 21, 2021
<sup>89</sup>Zr-labeled PSMA ligands for pharmacokinetic PET imaging and dosimetry of PSMA-617 and PSMA-I&T: a preclinical evaluation and first in man
Bastiaan M Privé, Yvonne H W Derks, Florian Rosar, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
October 8, 2021
[<sup>68</sup>Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [<sup>177</sup>Lu]Lu-PSMA-617 treatment
Steffie M B Peters, Regina Hofferber, Bastiaan M Privé, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 35) with videos related to
Sort By:
Page
of 4
Cancers
|
May 14, 2022
An Explorative Study of the Incidental High Renal Excretion of [<sup>18</sup>F]PSMA-1007 for Prostate Cancer PET/CT Imaging
Youssra Allach, Amina Banda, Willemijn van Gemert, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 14, 2022
Thoughts on "Tumor Sink Effect in <sup>68</sup>Ga-PSMA-11 PET: Myth or Reality?"
Bastiaan M Privé, Steffie M B Peters, Maike J M Uijen, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
August 5, 2022
[<sup>89</sup>Zr]Zr-PSMA-617 PET/CT in biochemical recurrence of prostate cancer: first clinical experience from a pilot study including biodistribution and dose estimates
Florian Rosar, Andrea Schaefer-Schuler, Mark Bartholomä, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
February 10, 2023
Population pharmacokinetic dosimetry model using imaging data to assess variability in pharmacokinetics of <sup>177</sup> Lu-PSMA-617 in prostate cancer patients
Hinke Siebinga, Bastiaan M Privé, Steffie M B Peters, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
July 4, 2021
Intra-therapeutic dosimetry of [<sup>177</sup>Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome
Steffie M B Peters, Bastiaan M Privé, Maarten de Bakker, et al.
Nuclear Medicine Communications
|
January 4, 2023
Kidney absorbed radiation doses for [ 177 Lu]Lu-PSMA-617 and [ 177 Lu]Lu-PSMA-I&T determined by 3D clinical dosimetry
Maike J M Uijen, Bastiaan M Privé, Carla M L van Herpen, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
February 22, 2023
Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies
Bastiaan M Privé, Mohamed A Boussihmad, Bart Timmermans, et al.
EJNMMI Research
|
January 24, 2023
Optimization of the radiation dosimetry protocol in Lutetium-177-PSMA therapy: toward clinical implementation
Steffie M B Peters, Maaike C T Mink, Bastiaan M Privé, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
December 21, 2021
<sup>89</sup>Zr-labeled PSMA ligands for pharmacokinetic PET imaging and dosimetry of PSMA-617 and PSMA-I&T: a preclinical evaluation and first in man
Bastiaan M Privé, Yvonne H W Derks, Florian Rosar, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
October 8, 2021
[<sup>68</sup>Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [<sup>177</sup>Lu]Lu-PSMA-617 treatment
Steffie M B Peters, Regina Hofferber, Bastiaan M Privé, et al.
Page
of 4